# Longevity Startup Doses First Human in Bid to Reverse Age-Related Sight Loss

> **Platform:** [SPIDITS AI](https://spidits.com/) — Real-Time AI News & Market Intelligence  
> **Published:** 2026-06-09T13:23:53.000Z  
> **Category:** PRODUCT_LAUNCH  
> **Impact Score:** 90/100  
> **Primary Source:** [Wired](https://www.wired.com/story/longevity-startup-doses-first-human-in-bid-to-reverse-age-related-sight-loss)  
> **Canonical Citation:** [https://spidits.com/timeline/longevity-startup-doses-first-human-in-bid-to-reverse-age-related-sight-loss](https://spidits.com/timeline/longevity-startup-doses-first-human-in-bid-to-reverse-age-related-sight-loss)

## Executive Summary
The FDA recently approved the cellular rejuvenation therapy ER-100 for human clinical trials. While vision is the first target, it could have applications for...

## Referenced Coverage & Sources
- **[Wired](https://www.wired.com/story/longevity-startup-doses-first-human-in-bid-to-reverse-age-related-sight-loss)**: Longevity Startup Doses First Human in Bid to Reverse Age-Related Sight Loss — _The FDA recently approved the cellular rejuvenation therapy ER-100 for human clinical trials. While vision is the first target, it could have applications for..._

---
*Synthesized by SPIDITS AI Market Intelligence Desk. Track live AI news, model releases, and funding: [https://spidits.com](https://spidits.com)*